Current Studies

To apply online for any of our studies, click here.

SL1506-001: One time blood draw for HIV+ patients who have a viral load equal or greater than 600.

SL1506-001: One time blood draw for patients with Hepatitis.

SL1506-001: One time blood draw for pregnant women that are known to be HIV positive or from pregnant women that are  at high risk for HIV exposure.

GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Primary Objective of this study is to evaluate the safety and tolerability of a 10-dose regimen of GS-9620 in HIV-1 infected controller on antiretroviral treatment and during analytical treatment interruption following GS-9620 dosing. 

This study will test an experimental drug named GS-9620 which is being developed to help the immune system control HIV. 

Antiretroviral meds can reduce HIV to low levels in the blood but these meds do not eliminate the HIV infection, and a small amount of the virus continues to live in the body in sleeper cells even when the viral load is low or below the limit of detection. 

The purpose of this study is to determine how well your body tolerates GS-9620, how long GS-9620 stays in your body, and how GS-9620 affects the HIV infection and sleeper cells in your body.

Some of the inclusions:

  • HIV-1 infected subjects of >18 years at Pre-Baseline/Day -13.
  • Pre-antiretroviral therapy with viral load between 50 and 5,000 copies/ml.

Some of the exclusions:

  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 90 days prior to screening.
  • Chronic hepatitis B infection.
  • Hepatitis C antibody positive.

Some potential risks include:

  • Transient flu-like symptoms (such as chills and fever).
  • Transient increases in plasma HIV-1 viral load that are expected to resolve by the end of the dosing period.

GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/emtricitabine/Tenofovir Alafenamide in HIV-1 infected Subjects who are Virologically Suppressed.

Some of the inclusions are:

  • At least 18 years of age.
  • Currently receiving an antiretroviral regimen of DTG+F/TAF or DTG+F/TDF for at least 3 months.

Some of the risks include:

  • Diarrhea, Headache, Nausea, Fatigue, Joint pain, Back pain.

ViiV 204862-Tango: A Phase 3, randomized, multicenter, parallel-group noninferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed.

Some of the inclusions:

  • At least 18 years of age.
  • HIV-1 infected men or women.

Some of the exclusions:

  • Women who are breastfeeding or plan to become pregnant or breastfeed during the study.
  • Any evidence of an active CDC  stage 3 disease.
  • Unstable liver disease, Hep B or Hep C.

ARLG_Pnaat-Yr3 (Swab Study): Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Extragenital Sites.

Primary Study Objective:

  • Neisseria gonorrhoeae in rectal swabs
  • Neisseria gonorrhoeae in throat swabs
  • Chlamydia trachomatis in rectal swabs
  • Chlamydia trachomatis in throat swabs

Study Population: Patients present for STD testing for Neisseria gonorrhoeae and Chlamydia trachomatis. A one-time study visit.